ASSURE-CSU- RESOURCE USE AND ECONOMIC BURDEN IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA IN ITALY

Author(s)

Roccia A¹, Rigoni L¹, Cawson MR², McBride D², Canonica GW³, Balp M⁴
¹Novartis Farma, Origgio, Italy, ²RTI Health Solutions, Manchester, UK, ³University of Genoa, Genoa, Italy, ⁴Novartis Pharma AG, Basel, Switzerland

Presentation Documents

PHS58-roccia-a-sup-1-sup-rigoni-l-sup-1-sup-cawson-mr-sup-2-sup-mcbride-d-sup-2-sup-canonica-gw-sup-3-sup-strong-u-balp-m-u-sup-4-sup-strong-br-sup-1-sup-novartis-farma-origgio-italy-sup-2-sup-rti-health-solutions-manchester-uk-sup-3-sup-un ...

OBJECTIVES: ASSURE-CSU, an observational, multicenter study conducted in seven countries (UK, Germany, Canada, France, Italy, Spain, Netherlands), evaluated the humanistic and economic burden of disease in patients with chronic spontaneous/idiopathic urticaria (CSU) inadequately controlled by treatment. We present data on healthcare resource utilization and work impairment in Italy.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHS58

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation